12:00 AM
 | 
Oct 21, 2013
 |  BC Week In Review  |  Company News  |  Other News

AMAG Pharmaceuticals, Silverstrand Investments hematology news

The U.S. Supreme Court will not review an appeal of a case involving anemia drug Feraheme ferumoxytol. In a February ruling on Silverstrand Investments, et al. v. AMAG Pharmaceuticals, et al. the First Circuit Court of Appeals affirmed in part a decision by the U.S. District Court for the District of...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >